fda approval in sclc, partial hold in myeloma trials, nccn guideline update in crc, and more
Published 5 years ago • 184 plays • Length 12:53
Download video MP4
Download video MP3
Similar videos
-
10:55
fda approval in myeloma, label update in her2 breast cancer, and more
-
11:34
fda approval in cll, recommendation in sts, partial hold on cervical cancer trial, and more
-
8:12
fda approvals in hcc, sclc, and nsclc, priority review in rare blood cancer, and more
-
10:49
fda approvals in myeloma, nets, and of a biosimilar, priority review in ovarian cancer, and more
-
9:17
fda approvals in cscc, nsclc, and myeloma, breakthrough designation in prostate cancer, and more
-
10:01
fda approvals in sclc and a biosimilar, and japanese approvals in aml, ntrk tumors, and more
-
7:23
fda approval in nsclc, priority review in sclc, 2018 sabcs highlights, and more
-
10:46
fda approval in all, priority reviews in cml and breast cancer, and more
-
9:02
fda approval in sarcoma, priority reviews in mcrpc and myeloma, and more
-
11:50
fda approval in myeloma, priority review in dlbcl, application accepted of a biosimilar, and more
-
10:20
fda approvals in myeloma and thyroid cancer, priority review and nda in nsclc, and more
-
9:25
fda approvals in large b-cell lymphoma and melanoma, priority reviews in cscc and nsclc, and more
-
1:08:52
integrating new options into the sclc treatment arsenal to improve patient outcomes
-
1:24:26
assessing the impact of therapeutic advances in sclc
-
7:28
fda approvals in pml, nsclc, and breast cancer, priority review in dlbcl, and more
-
9:46
fda approval in cll, recommendation in nsclc, missed endpoint in gbm study, and more
-
1:28
dr. forster on recent data with lurbinectedin in sclc
-
11:56
additional advances in non–small cell lung cancer research and clinical trials with ticiana leal, md
-
41:11
optimizing treatment selection, sequencing, and tolerability in small cell lung cancer
Clip.africa.com - Privacy-policy